Advanced therapy medicinal products
You must score at least 70% in this module to pass. Ensure you have read ‘Advanced therapy medicinal products: a comprehensive overview for the pharmacy professional’ before attempting to complete the module.
This module can be taken up to three times. Once you have passed, you can view the correct answers and download a certificate as a record of your learning.
Additional CPD modules are available in the ‘My CPD’ section of your account.
0 of 15 questions completed
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
0 of 15 questions answered correctly
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
A tissue-engineered advanced therapy medicinal product (ATMP) is:CorrectIncorrect
A gene ATMP can be described as:CorrectIncorrect
Which of following licensed ATMPs is NOT administered in a single dose?CorrectIncorrect
In the UK, ATMPs are evaluated and authorised centrally by the:CorrectIncorrect
Which of the following is the most commonly used ATMP in the UK?CorrectIncorrect
The purpose of lymphodepletion prior to chimeric antigen receptor T-cell (CAR-T) therapy is to:CorrectIncorrect
Where is up-to-date information on ATMP clinical trials located?CorrectIncorrect
Spherox is an example of which class of ATMP?CorrectIncorrect
Which of the following statements about autologous human corneal epithelial cells (Holoclar) is NOT true?CorrectIncorrect
Which of the following statements about onasemnogene abeparvovec (Zolgensma) is NOT true?CorrectIncorrect
What is the main reason for the lack of certainty in cost-effectiveness estimates of ATMPs?CorrectIncorrect
Who undertakes horizon scanning for ATMPs?CorrectIncorrect
Who has the ultimate responsibility for safety and governance of all medicines?CorrectIncorrect
The National Institute for Health and Care Excellence recently recommended a new ATMP, even though its cost-effectiveness – at £120,000 per quality-adjusted life year gained – exceeded the usual threshold by about £100,000. Which of the following factors might have justified this decision?CorrectIncorrect
There may be benefits to the NHS of using innovative payment methods for ATMPs. These could include risk-sharing schemes. Which of the following is a reason for needing alternative arrangements?CorrectIncorrect